Nasus Pharma Ltd. (NSRX) Stock Forecast
NSRX analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $19.67 average of analyst targets
- Upside to target
- +518.4% from the latest close
- Next earnings
- —
- 52-week range
- $2.01 – $9.15
NSRX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NSRX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | — | — | 2 |
| Current fiscal year (2026) | −$1.13 | −$1.28 | −$0.84 | −$0.72 | −56.9% | 3 |
| Next fiscal year (2027) | −$1.13 | −$1.46 | −$0.81 | −$1.13 | +0.3% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NSRX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
NSRX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NSRX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | $0.00 | $0.00 | $0.00 | −100.0% | 2 up · 0 down |
| Current fiscal year (2026) | −$1.39 | −$1.39 | −$1.13 | −$1.13 | −$1.13 | −18.7% | 2 up · 1 down |
| Next fiscal year (2027) | −$1.32 | −$1.32 | −$1.13 | −$1.13 | −$1.13 | −14.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NSRX earnings surprises
Reported EPS vs the consensus estimate for the last 5 quarters; NSRX beat in 2 of 5.
What analysts expect from NSRX
The average price target is $19.67, 518.4% above the latest close of $3.18. Analysts expect earnings of −$1.13 per share for 2026, −56.9% from a year earlier. For 2027 the average estimate is −$1.13 per share. Nasus Pharma beat the EPS estimate in 2 of the last 5 quarters.
Related: NSRX income statement, NSRX key metrics, NSRX chart. See the NSRX stock overview for the latest quote and news.
NSRX forecast FAQ
What is Nasus Pharma's price target?
The average analyst price target for Nasus Pharma is $19.67, 518.4% above the latest close of $3.18.
What is Nasus Pharma's EPS forecast?
Analysts forecast −$1.13 per share for 2026 (range −$1.28 to −$0.84); for 2027 the estimate is −$1.13.
Does Nasus Pharma usually beat earnings estimates?
Nasus Pharma reported EPS at or above the analyst estimate in 2 of the last 5 quarters.